STERIS STE

Reference table

1. What it is

STERIS plc (NYSE: STE) is an Ireland-domiciled, Ohio-run global leader in infection prevention. Its fiscal year ends March 31 (FY26 = year ended 2026-03-31). The company runs three segments:

• Healthcare (~72% of revenue) — sterilization and washing capital equipment, surgical consumables, endoscope reprocessing, and a large, sticky service and repair business for hospitals and surgical centers. Q4 FY26 Healthcare revenue $1.14B, +7%, with 9% service growth.
• Applied Sterilization Technologies (AST) (~19%) — outsourced contract sterilization of medical devices (gamma, e-beam, ethylene oxide, X-ray) for device manufacturers. High-margin, recurring, capacity-gated. Q4 AST revenue $289M, +6% reported (+2% organic — capital-equipment lumpiness).
• Life Sciences (~9%) — sterilizers, washers, cleanroom chemistries and consumables for pharma/biopharma manufacturing. Q4 revenue $163M, +9%.

Revenue mix (FY26, from FMP segmentation):

• By type: Product $3.06B (52%) · Service $2.88B (48%). The near-half service mix is the quality tell — it's recurring, high-retention, and less cyclical than capital equipment.
• By geography: United States $4.33B (73%) · other foreign $1.49B · Ireland $0.11B. US-concentrated, which ties demand to US hospital procedure volumes and exposes the P&L to US tariff/inflation dynamics (management explicitly cited tariffs pressuring Healthcare operating income in Q4).

This is a wide-moat, low-drama compounder: essential, recurring, non-discretionary demand, tied to the secular growth of surgical procedure volumes and the rising installed base of sterilized medical devices.

2. The expert thesis

There is no expert coverage of STE in the Synthos knowledge base. total_claims = 0; there are zero net-bullish (or bearish) voices and zero traceable claim_ids. honesty comes first, so we state it plainly: nothing in this note rests on expert conviction. The verdict below is entirely fundamentals- and quant-driven — the reported financials, the analyst estimates and guidance (FMP + SEC 8-K), the valuation math, and the technical picture.

For context only (not Synthos conviction): the sell-side is constructive — 11 Buy, 2 Hold, 0 Sell, consensus rating "Buy," FMP letter rating A-, and a price-target consensus of $269.5 (a tight $269–$270 band from a thin set of targets). We treat that as the market's framing to react to, not as our anchor.

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.

Synthos fair value = the base case, ~$235 (+8%), with the full $175–$285 span as the honest range. Our base sits below the Street's $270 consensus — the sell-side is anchoring on ~24× forward adj EPS, which we think is rich for a mid-single-digit organic grower in a downtrend; we underwrite ~20–21× and get a more modest single-digit upside. This is a tracked call — the Forecaster Scorecard grades it once it matures.

4. Exponential Potential

Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). STE is a solid compounder with essentially no exponential profile:

• Forward growth: revenue CAGR FY26→FY29E ~6.5% ($5.94B → ~$7.18B, per FMP consensus); GAAP EPS CAGR ~18% ($7.93 → ~$13.20) — but note the EPS growth is flattered by amortization roll-off, buybacks (new $1B repurchase authorization) and margin, not by volume. On adjusted EPS the guide is a steadier ~9–11%/yr.
• Acceleration (the 2nd derivative) is slightly negative: reported revenue growth is +9% FY26 → +7–8% guided FY27. There's no inflection here — it's a mature market growing with procedure volumes plus tuck-in M&A.
• Room to run: the infection-prevention/contract-sterilization TAM is large, but STERIS is already the leader — this is share consolidation and end-market growth, not a greenfield land-grab. At ~$21B market cap the law of large numbers plus mid-single-digit organic growth caps any multibagger case.
• Reinvestment runway: disciplined, modest — ~$375M/yr capex (incl. a new $60M Ohio sterility-assurance plant), FCF ~$850M guided FY27, returned via dividend + buyback. Healthy, but a return-of-capital profile, not a reinvest-for-hypergrowth one.

Exponential Potential: Low (3/10). Own STE for dependable high-single/low-double-digit total returns (organic growth + margin + buyback + ~1.2% dividend), not for a fast multibagger. That's not a knock on quality — it's an honest read of the math.

5. Financials (real numbers — FMP annual/quarterly + SEC 8-K)

• Revenue: FY26 $5.94B, +8.7% (FY25 $5.46B, +6.2% on FY24 $5.14B). Reported +9% / organic +7% constant-currency. Steady, not spectacular.
• Quarterly trajectory: Q1'26 $1.39B → Q2 $1.46B → Q3 $1.50B → Q4 $1.59B. Normal seasonal build, low volatility.
• Margins: gross 44.2% TTM (rising from ~43% FY25), EBITDA margin 30.8%, operating ~18.6%, net 13.2%. Management flagged tariffs + inflation as the main offsets to price/volume gains in Healthcare — a margin watch-item.
• Earnings: GAAP net income $785M FY26, EPS $7.93 (up from $6.24 FY25). Adjusted EPS $10.17 (+10% vs $9.22 FY25) — the number management and the Street anchor on; the GAAP/adjusted gap is mostly acquired-intangible amortization.
• Cash flow: operating CF $1.34B, capex −$369M, FCF $972M FY26 (management cites $983M; +25% YoY). FCF/share ~$9.92; FCF yield ~4.6%. Clean, high-quality cash conversion (income quality 1.7×).
• Balance sheet: total debt $2.09B, cash $440M, net debt $1.65B → net-debt/EBITDA 0.9× (down from ~2.0× in FY24 post-Cantel deleveraging). Investment-grade, interest coverage 18×, current ratio 2.1×. A genuinely strong balance sheet. Note: goodwill + intangibles are 54% of assets ($5.8B) — a legacy of the Cantel/US Endoscopy acquisitions; watch for impairment if returns disappoint.

6. Valuation — priced in or room?

STE is fairly-to-fully valued, not cheap. On trailing numbers it's 27.4× GAAP EPS, or ~21× adjusted EPS ($218.20 / $10.17). On the forward guide, ~19.5× FY27E adjusted EPS (mid-point $11.20) — a reasonable but not bargain multiple for a defensive mid-single-digit grower. EV/EBITDA 12.5× and EV/sales 3.9× are middling for med-tech quality. The PEG on adjusted EPS (~2×) says you're paying up relative to the growth rate.

The bull's defense is that the multiple compresses as adjusted EPS compounds ~10%/yr and the buyback shrinks the share count. The bear's rebuttal is that a ~7%-organic-growth business shouldn't command a growth multiple, and the market seems to agree — hence the ~10% 12-month decline while the S&P rose ~20%. Street targets (context): consensus $270, high $270, low $269 — a tight, constructive band implying ~24× forward adj EPS. We anchor lower (~20–21×) and get a ~$235 base case; the Street's optimism is the gap to watch. This is a quality-at-a-full-price name — worth owning on a pullback, not chasing here.

7. Technicals (from the tech block)

• Trend: down. $218 sits just above the 50-DMA ($212) but below the 200-DMA ($237) — the 50 is below the 200 (death-cross posture). MACD only marginally positive (+0.28). This is a stock trying to base, not one in an uptrend.
• Location: −19% off the 52-week high ($268.65), +9% off the 52-week low ($199.40). Max drawdown from peak −18.8% — a real correction, not a leadership breakout.
• Momentum: RSI(14) 63 — firm but not overbought; consistent with the recent bounce off the lows toward the 50-DMA.
• Relative strength (the tell): STE −10.1% 12-mo vs SPY +20.6% and QQQ +30.3%; −0.8% 3-mo vs SPY +13.7%. Persistent underperformance of both the market and growth — the opposite of a momentum name.
• Read: technicals do not confirm a buy. The stock is below its 200-day line and has lagged badly for a year. A reclaim of the 200-DMA (~$237) on volume would be the technical green light; until then, the chart argues for patience — consistent with the Watch verdict.

8. Moat & competitive position

STERIS's moat is real and multi-layered: (1) scale and breadth — the broadest infection-prevention portfolio, spanning capital equipment, consumables and service across hospital and pharma; (2) switching costs and a service annuity — once STERIS equipment and reprocessing workflows are installed, the recurring service/consumable stream is sticky and high-margin (~half of revenue is service); (3) AST as a quasi-utility — contract sterilization is capacity-gated, regulation-heavy, and consolidated among few players (STERIS and Sotera/Nordion-type peers), giving pricing power; (4) regulatory/validation barriers — sterility assurance is mission-critical and validated, so customers don't switch casually. Returns on capital (ROIC ~8.5%, ROE 11%) are solid though not spectacular, weighted down by the acquisition-heavy asset base.

Peer set (FMP, market cap): the FMP peer list is a broad med-tech basket rather than pure sterilization comps — Waters $24.7B, West Pharmaceutical $25.8B, Zimmer Biomet $16.9B, Labcorp $23.5B, Quest Diagnostics $23.9B, DexCom $27.5B, Biogen $31.9B, Insulet $11.4B, Smith & Nephew $12.8B, Philips $26.9B. STE sits mid-pack on size; its closest economic analogues (contract sterilization, sterility assurance) aren't in this list. Versus the basket, STE offers lower growth but higher defensiveness than the diagnostics/device names.

9. Management, capital allocation & guidance

• Capital allocation: disciplined and shareholder-friendly. FY26 returned ~$236M in buybacks and ~$242M in dividends; the Board authorized a new $1B repurchase program (May 2026). Capex is modest (~$375M guided FY27, including a $60M Ohio consolidation plant). Post-Cantel deleveraging took net-debt/EBITDA from ~2.0× to 0.9× — a clean, conservative sheet. Dividend $2.52/yr (~1.2% yield), payout ~31% — well-covered and growing.
• Insider activity: the sampled window (June–July 2026) shows routine, non-alarming activity — mostly F-InKind tax-withholding dispositions on vesting and a director option exercise; one small officer sale (~$0.3M). No cluster of discretionary insider selling that would flag concern.
• Management's own guidance — FY27 outlook (from the SEC 8-K earnings release, 2026-05-11 — self-interested words, half-weighted): management guides reported revenue +7–8% (constant-currency organic +6–7%), adjusted diluted EPS $11.10–$11.30 (+9–11% vs $10.17), at a ~25% tax rate; capex ~$375M and free cash flow ~$850M. This is a real earnings release (revenue, segment detail, explicit forward outlook), so we weight it as credible-but-management's-own-book. It reads as steady mid-single-digit organic growth converted into low-double-digit adjusted EPS via price, mix, margin and buyback — exactly the compounder profile our scores reflect. Note FY27 FCF guidance (~$850M) is below FY26's $983M, reflecting the new plant investment and working-capital normalization — a modest near-term FCF headwind to watch.

10. Catalysts & what to watch

• Next earnings: 2026-08-05 (Q1'27; Street EPS $2.52, revenue ~$1.50B). The key lines: Healthcare organic growth and operating margin (tariff/inflation offset) and AST capital-equipment trend (the swing factor on organic growth).
• Procedure volumes: US hospital surgical/procedure volumes are the demand driver — acceleration is the bull trigger, softness the bear trigger.
• Margin vs tariffs/inflation: management flagged tariffs pressuring Healthcare operating income — watch whether price/productivity outpaces the drag.
• Buyback execution: how aggressively the new $1B authorization is deployed at these levels supports EPS.
• Technical: a reclaim of the 200-DMA (~$237) would flip the chart from "Watch" toward "add."

Thesis tripwires (what would change the call): two consecutive quarters of organic revenue below ~5%; adjusted-EPS guidance cut; a Healthcare margin break from tariffs/inflation; or a goodwill/intangible impairment. A pullback into the low-$190s (toward the 52-wk low) with intact fundamentals would, conversely, make the risk/reward clearly attractive.

11. Key risks

• Valuation / de-rating (the main risk): ~27× trailing GAAP EPS for ~7% organic growth offers little margin; the 12-month downtrend suggests the market is already re-rating.
• Tariffs & input inflation: explicitly cited by management as an offset to Healthcare operating income — a live margin threat given US manufacturing/import exposure.
• Procedure-volume cyclicality: demand tracks US hospital surgical volumes; a slowdown (macro, staffing, or reimbursement-driven) hits the Healthcare segment.
• AST capital-equipment lumpiness: the highest-margin segment's reported growth swings with capital-equipment timing (Q4 FY26 showed a 62% capital-equipment decline masked by service growth).
• Acquisition-heavy balance sheet: goodwill + intangibles are 54% of assets (Cantel legacy) — impairment risk if returns disappoint; integration/M&A dependence for above-organic growth.
• No expert coverage: with zero KB claims, there is no independent conviction cross-check — the call is model-only and should be sized accordingly.

12. Verdict, position sizing & monitoring

Watch. STERIS is a genuinely high-quality, wide-moat, low-beta infection-prevention leader with a fortress balance sheet (net-debt/EBITDA 0.9×), strong FCF ($972M), a growing dividend and a fresh $1B buyback — a textbook defensive compounder. But two things hold it back from a Buy today: (1) the valuation is full (~27× trailing GAAP / ~19.5× forward adjusted) for only mid-single-digit organic growth, and (2) the technicals are in a downtrend (below the 200-DMA, −10% over 12 months vs a +20% market). Our base-case fair value (~$235, +8%) sits below the Street's $270. With no expert coverage to add conviction, the honest call is to keep it on the list and buy on weakness or a fundamental re-acceleration, not to chase it here.

• Sizing: if bought, a defensive-quality satellite, ~1–3% — and ideally scaled in on a pullback toward the low-$200s / high-$190s or a reclaim of the 200-DMA. Not a core conviction position given zero KB breadth.
• Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $218.20.
• Single biggest risk: de-rating — paying a premium multiple for slow growth, which the past year's decline has already begun to price in.

Provenance & disclosures

• Traceability: 0 KB claims, breadth 0 — there is no expert coverage of STE in the Synthos knowledge base, and this note says so plainly. The verdict is fundamentals- and quant-driven. Fabricated conviction is structurally impossible (claim-ID reconciliation); here, no claim_ids exist to cite.
• Data as-of: fundamentals 2026-03-31 (FY26, ended March 2026) · estimates & prices 2026-07-02/03 · management guidance from SEC 8-K dated 2026-05-11. Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates.
• Management caveat: FY27 guidance is management's own book, half-weighted by design.
• Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
• Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").